Abstract:Hepatitis B virus (HBV) infection is an important public health issue. Hong Kong's universal HBV immunisation programme for newborns began in 1988.1 This programme consists of administering hepatitis B immunoglobulin (HBIg) to infants born to hepatitis B surface antigen (HBsAg)–positive mothers, along with the first dose of the HBV vaccine at birth. The second and third doses of the vaccine are typically given in Maternal and Child Health Centres at 1 and 6 months, respectively. Notably, the proportion of HBsAg-positive pregnant women has steadily decreased in recent years, from 5.2% in 20162 to 2.4% in 2023 (unpublished data). Despite a 99.8% HBsAg screening rate among antenatal women, together with 99.5% coverage for both HBIg and HBV vaccinations in newborns of HBsAg-positive mothers,2 a local study3 of 641 HBsAg-positive pregnant women showed that the overall mother-to-child transmission (MTCT) rate remained 1.1%, indicating immunoprophylaxis failure. To align with the World Health Organization's (WHO) goal of eliminating viral hepatitis as a public health threat by 2030,4 and specifically to achieve the WHO target of <0.1% HBsAg prevalence among 5-year-old children by that year, further reduction of MTCT of HBV has been targeted by the multidisciplinary Steering Committee on Prevention and Control of Viral Hepatitis, established in 2018 and chaired by the Director of Health and the Chief Executive of Hospital Authority.5 As an obstetrics representative on the Steering Committee, the first author had the opportunity to present a literature review for use in formulating the action plan. Three strategies were considered: (1) maintaining the current approach of administering HBIg and HBV vaccinations to newborns of HBsAg-positive mothers, (2) conducting another randomised controlled trial on the use of tenofovir in further prevention of MTCT of HBV, and (3) implementing a universal programme to use tenofovir for this purpose. Although two major randomised controlled trials,6 7 both published in The New England Journal of Medicine , appeared to reach conflicting conclusions, the MTCT of HBV rates were zero in both the Mainland China study6 (n=92, per-protocol) and the Thailand study7 (n=147). The safety of tenofovir in pregnancy has also been established. Rebound increases in alanine aminotransferase after tenofovir discontinuation were mild in most cases (acute hepatic exacerbation, defined as alanine aminotransferase elevation of >300 IU/L, occurred in 6% of the tenofovir group vs 3% of the control group7). The administration of antivirals to HBsAg-positive pregnant women with high HBV DNA levels has been recommended by the American Association for the Study of Liver Diseases, European Association for the Study of the Liver, Asian Pacific Association for the Study of the Liver, and Advisory Committee on Immunization Practices.5 Despite these recommendations, the WHO had not made any recommendations by 2018. The Steering Committee ultimately decided to proceed with option 3.5

Challenges for hepatitis B control in Asia‐Pacific areas: Consolidating vaccination and rolling‐out antiviral therapies

Comprehensive Approach to Controlling Chronic Hepatitis B in China

Advances in treatment and prevention of hepatitis B

Current Advances in the Elimination of Hepatitis B in China by 2030

Global importance of new treatment strategies to efforts to control hepatitis B virus

Role of General Practitioners in Prevention and Treatment of Hepatitis B in China

Management of chronic hepatitis B: experience from China

Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period.

Global Perspectives on the Hepatitis B Vaccination: Challenges, Achievements, and the Road to Elimination by 2030

Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030

Can we eliminate mother-to-child transmission of hepatitis B virus in Hong Kong by 2030?

Prospects for Controlling Hepatitis B Globally

The role of Traditional Chinese medicine in anti-HBV: background, progress, and challenges

Countdown to 2030: Eliminating Hepatitis B Disease, China

Hepatitis B: Overview of the Burden of Disease in the Asia‐Pacific Region

Chronic Hepatitis B: Whom to Treat and for How Long? Propositions, Challenges, and Future Directions

Combating hepatitis B and C by 2030: achievements, gaps, and options for actions in China

The roadmap towards cure of chronic hepatitis B virus infection

Global burden of hepatitis B virus: current status, missed opportunities and a call for action

Treatment of chronic hepatitis B virus infection: an Asia-Pacific perspective.

Therapeutic strategies for hepatitis B virus infection: towards a cure